Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Strategic Research Report

Scope of the Report

The global Duchenne Muscular Dystrophy (DMD) Therapeutics market size is predicted to grow from US$ 2,348 million in 2025 to US$ 5,088 million in 2032; it is expected to grow at a CAGR of 11.8% from 2026 to 2032.

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

The Duchenne muscular dystrophy (DMD) treatment market is primarily driven by the following factors:

I. Disease Burden and Unmet Needs

High Disability and Mortality Rates:

DMD is a progressive muscle wasting disease. Patients typically lose the ability to walk around age 10 and die from cardiopulmonary failure between the ages of 20 and 30. With approximately 300,000 cases worldwide and over 70,000 in China, the disease poses a significant social burden.

If a female carrier gives birth to a boy, there is a 50% chance that the child will inherit the disease, creating a high family genetic risk.

Limitations of Existing Treatments:

Current mainstream treatments, including corticosteroids (such as deflazacort) and topical exon-skipping drugs (such as Exondys 51), can only delay the disease, not cure it, and require long-term use with significant side effects.

There is a lack of universal treatments, which only cover specific gene mutation types (such as exon 51/53 skipping), limiting their applicable population. Improved Diagnosis Rate:

With improved medical infrastructure and urbanization, China's DMD diagnosis rate is expected to rise from approximately 30% in 2022 to over 50% in 2025, bringing more patients into the treatment-needing population.

II. R&D Progress and Pipeline Breakthroughs

Breakthroughs in Gene Therapy and Oligonucleotide Technologies:

Gene therapies, such as Sarepta's SRP-9001 (microdystrophin delivered via an AAVrh74 vector) and Faith Pharmaceuticals' BBM-D101 (engineered AAV vector), achieve long-term protein expression with a single dose. Clinical trials have shown a significant increase in the percentage of positive fibers.

Huida Gene's CRISPR-Cas12 gene editing therapy has entered clinical trials, targeting gene mutation repair.

Oligonucleotide therapies, including antisense oligonucleotides (ASOs) and next-generation peptide-coupled oligonucleotides (PPMOs), such as PepGen's PGN-EDO51 and Entrada's ENTR-601-44, enhance cellular uptake and lysosomal escape, improving efficacy and reducing dosage. Active Domestic R&D Pipeline:

Over 10 DMD drugs have entered clinical trials in China, including gene editing (such as Huida Gene's CRISPR-Cas12), AAV gene therapy (Jinwei Bio's JWK007), and mini-protein drugs (Faith Pharmaceuticals' BBM-D101). Some have received FDA orphan drug designation and are expected to be launched after 2026.

III. Policy Support and Optimized Payment Environment

Policy Support for Rare Diseases:

US: The DUX Act extends the market exclusivity period for DMD orphan drugs to 7.5 years, and the accelerated approval process shortens drug launch time by 34%.

China: DMD will be included in the second round of rare disease listings in 2024, promoting domestic R&D. Medical insurance coverage has expanded, with vamorolone included in the national medical insurance negotiations. The price of domestically produced gene therapies is expected to drop below 2 million yuan by 2026.

Improved Affordability:

North America: Commercial insurance companies (such as UnitedHealthcare) have prioritized DMD gene therapy reimbursement, with medical insurance coverage exceeding 80%. In Europe, reimbursement rates for products that pass HTA assessment exceed 80%, but product launches lag 9-15 months behind those in the US.

Asia-Pacific: Markets such as China, Japan, and South Korea are experiencing significant growth, with policies and capital jointly driving therapeutic accessibility.

The DMD therapy market is driven by disease severity, technological breakthroughs, and favorable policies. Gene editing and RNA therapies will dominate the future, but high costs and production capacity bottlenecks (such as AAV vector production) still need to be overcome. Companies need to focus on technological innovation and payment model optimization to address unmet medical needs.

This report presents a comprehensive overview of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Exondys
• Emflaza
• Translarna
• Others

Segment by Product Form

• Hormonal Drugs
• Exon Skipping
• Small Molecule Drugs
• Others

Segment by Sales Channels

• Online Sales
• Offline Sales

Segment by players, this report covers

• Sarepta Therapeutics
• ReveraGen BioPharma
• Sperogenix
• ReveraGen BioPharma Inc .
• Belief BioMed
• PTC Therapeutics
• Santhera Pharmaceuticals
• Italfarmaco

Segment by Application

• Hospitals
• Clinics
• Home Care

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospitals, Clinics, Home Care evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact